Up to now, two PD1 inhibitors Nivolumab and Pembrolizumab and one PD-L1 inhibitor Atezolizumab have been approved as standard treatment options for NSCLC patients (48). The gene discussed is CD274; the disease is non-small cell lung carcinoma.